Kura oncology, inc. (KURA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Operating Activities
Net loss

-63,140

-60,447

-35,434

-27,560

-22,625

-30

-28

-27

-27

-22

Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense

9,409

8,654

4,545

2,089

2,259

-

-

-

-

-

Non-cash interest expense

-

184

118

42

37

-

-

-

-

-

Loss on debt extinguishment

-

-498

-

-

-

-

-

-

-

-

Non-cash license fee expense

-

-

-

-

500

-

-

-

-

-

Change in value of derivative liability

-

-

-

-

-268

-

-

-

-

-

Non-cash interest expense, related party

-

-

-

-

42

-

-

-

-

-

Depreciation expense

0

10

30

31

20

-

-

-

-

-

Amortization of premium and accretion of discount on marketable securities, net

1,103

1,935

260

-129

-171

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable, related party

-210

8

-79

-135

400

-

-

-

-

-

Prepaid expenses and other current assets

1,085

457

196

32

650

-

-

-

-

-

Other long-term assets

117

504

593

652

164

-

-

-

-

-

Accounts payable and accrued expenses

856

5,116

3,052

471

2,812

-

-

-

-

-

Prepaid expenses

-

-

-

-

-

-2

-1

1

0

0

Accounts payable and accrued expenses, related party

-

-

-

-167

803

-

-

-

-

-

Other long-term liabilities

210

234

218

165

-998

-

-

-

-

-

Proceeds from issuance of convertible notes

-

-

-

-

4,290

-

-

-

-

-

Increase (decrease) in accounts payable

-

-

-

-

-

2

-1

-1

0

1

Increase in accrued interest

-

-

-

-

-

6

5

4

3

1

Increase in accrued expenses

-

-

-

-

-

3

0

0

0

0

Net cash used in operating activities

-54,760

-48,655

-28,441

-

-

-15

-23

-24

-22

-19

Net cash used in operating activities

-

-

-

-25,349

-17,925

-

-

-

-

-

Investing Activities
Maturities and sales of marketable securities

181,246

158,143

77,217

68,605

6,000

-

-

-

-

-

Purchases of marketable securities

227,571

237,443

100,635

56,427

76,562

-

-

-

-

-

Purchases of property and equipment

-

-

-

-

64

-

-

-

-

-

Net cash provided by investing activities

-46,325

-79,300

-23,418

12,178

-70,626

-

-

-

-

-

Financing Activities
Payments on notes payable, stockholders

-

-

-

-

-

0

0

0

0

0

Proceeds from issuances of common stock, net

108,165

132,172

53,679

-

97,870

0

0

0

0

0

Proceeds from exercise of stock options and purchases under employee stock purchase plan

2,936

1,092

232

-

-

-

-

-

-

-

Proceeds from issuance of long-term debt, net

-

627

-

7,453

-

-

-

-

-

-

Repayment of long-term debt

-

1,250

-

-

-

-

-

-

-

-

Payment of fee related to long-term debt

-

-

344

-

-

-

-

-

-

-

Proceeds from issuance of convertible notes, related party

-

-

-

-

710

15

25

25

0

35

Net cash provided by financing activities

-

-

-

7,453

102,870

-

-

-

-

-

Net cash provided by financing activities

111,101

132,641

53,567

-

-

15

25

25

0

35

Net increase in cash, cash equivalents and restricted cash

10,016

4,686

1,708

-5,718

14,319

-0

1

0

-22

15

Supplemental disclosure of cash flow information:
Interest paid

430

641

627

352

-

-

-

-

-

-

Supplemental non-cash disclosures:
Warrants issued in connection with debt facility

-

-

-

172

-

-

-

-

-

-

Conversion of convertible notes and related accrued interest to common stock

-

-

-

-

4,327

-

-

-

-

-

Conversion of convertible notes and related accrued interest to common stock, related party

-

-

-

-

3,288

-

-

-

-

-